Delivery Order SPE2DB24D2101-SPE2DB25FKMSD
- Not listed
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $19,841.99 by the Defense Logistics Agency (DLA) on July 28, 2025, for the supply of Ondansetron HCl 4 mg tablets (500 count). This competitively awarded, firm fixed-price delivery order is expected to be completed by July 29, 2025, with performance occurring at the vendor's Conshohocken facility. The contract carries no set-aside designation,...
- The Defense Logistics Agency awarded a $5,101.23 delivery order to AmerisourceBergen Drug Corp for Ondansetron ODT 4 MG tablets (30-count units) on July 23, 2025, with an ultimate completion date of July 24, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Ondansetron is a widely used antiemetic medication commonly supplied to military and...
- The U.S. Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Ondansetron ODT 4 mg tablets in quantities of 30 units. This competitive award, with a ceiling value of $1,781.89, utilizes firm fixed-price delivery order terms and is scheduled for completion by July 23, 2025. The contract carries no set-aside designation, indicating it was awarded through open competition. AmerisourceBergen Drug Corp,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Ondansetron ODT 8 mg tablets in a 30-count package, with a ceiling value of $4,539.09 and a completion date of July 22, 2025. This is a firm fixed-price delivery order with no set-aside designation, awarded through open competition. The order will be fulfilled from AmerisourceBergen's corporate office located in Conshohocken, Pennsylvania. Ondansetron is an antiemetic...
- The Defense Logistics Agency awarded a $3,734.63 delivery order to AmerisourceBergen Drug Corp for 30 tablets of Ondansetron ODT 4 mg on July 26, 2025, with completion expected by July 28, 2025. This competitive award, issued under firm fixed pricing, represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), which is valued at $999,999,999.00 and extends through December 2026. The place of performance is located in...
- AmerisourceBergen Drug Corp was awarded a delivery order by the Defense Logistics Agency (DLA) on July 22, 2025, for the supply of Ondansetron ODT 4 mg tablets in quantities of 30 units. This is a firm fixed price delivery order with a ceiling value of $7,069.80 and an ultimate completion date of July 23, 2025. The contract carries no set-aside designation and represents a competitively awarded transaction. Performance will be executed from the contractor's location in Conshohocken,...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, was awarded a delivery order by the Defense Logistics Agency on July 24, 2025, for the supply of Ondansetron ODT 4 mg tablets in quantities of 30 units. This is a firm fixed-price contract with a ceiling value of $1,821.89 and an ultimate completion date of July 25, 2025. The award was made through open competition with no set-aside designation. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a $2,232.04 firm fixed price delivery order to AmerisourceBergen Drug Corp for Ondansetron ODT 4 mg tablets (30-count units) on July 18, 2025, with an ultimate completion date of July 21, 2025. This competitively awarded, non-set-aside contract calls for performance at the vendor's corporate office location in Conshohocken, Pennsylvania. Ondansetron is an antiemetic medication commonly used in military and federal healthcare settings to manage nausea and...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of Ondansetron ODT 4 mg tablets (30-count units) with a ceiling value of $8,001.71. This is a firm fixed price, non-competitive delivery order executed under the company's broader Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion global pharmaceutical support vehicle running through December 2026. The order will be performed at...
- The Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Ondansetron Orally Disintegrating Tablets (ODT) 4mg in a quantity of 30 tablets. This is a firm fixed-price delivery order with a ceiling value of $40,007.36 and an ultimate completion date of August 18, 2025. The contract is not designated as a set-aside and represents a competitive award. AmerisourceBergen Drug Corp, a major pharmaceutical...
- SPE2DB24D2101Indefinite Delivery Contract
- SPE2DB24D2101-SPE2DB25FKMSDDelivery Order
AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order by the Defense Logistics Agency on July 24, 2025, for Ondansetron ODT 4 mg tablets (30-count supply) with a contract ceiling value of $15,578.02. This firm fixed price delivery order, which is not set-aside for any socioeconomic category, is expected to be completed by July 25, 2025, and will be performed at the contractor's Conshohocken, PA location. Ondansetron is a commonly used anti-nausea medication in medical and surgical settings, reflecting the Defense Logistics Agency's ongoing need to maintain pharmaceutical inventories for military healthcare operations. This delivery order operates under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026, which serves as a comprehensive global pharmaceutical support vehicle. As a prime IDV holder, AmerisourceBergen supplies a wide range of pharmaceutical products and medical commodities to support military healthcare programs worldwide, including specialty medications, vaccines, and medical supplies across multiple therapeutic domains. The company's consistent receipt of competitively awarded, non-set-aside contracts demonstrates its established capability to meet federal procurement requirements and serve critical healthcare needs for the Defense Health Agency and other government medical systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $15.6k | 7/24/25 |